Open Government Portal
About this information
Open data is defined as structured data that is machine-readable, freely shared, used and built on without restrictions.
The key things to remember about open data are:
- #Availability and access#: the data must be available as a whole and at no more than a reasonable reproduction cost, preferably by downloading over the internet. The data must also be available in a convenient and modifiable form.
- #Re-use and redistribution#: the data must be provided under terms that permit re-use and redistribution including the intermixing with other datasets.
- #Universal participation#: everyone must be able to use, re-use and redistribute. There should be no discrimination against fields of endeavour or against persons or groups. For example, 'non-commercial' restrictions that would prevent 'commercial' use, or restrictions of use for certain purposes (e.g. only in education), are not allowed.
Before a drug is authorized for sale in Canada, it must be issued a DIN in accordance with the Food …
These guidelines are meant to help companies in the drug manufacturing industry and health care professionals understand how to comply …
Health Canada's drug products fact sheet describes how drugs are reviewed in Canada including how drugs are developed and submitted …
How to access a list of generic drug submissions currently under review.
For eligible submissions accepted into review on or after October 1, 2018, the submission 'class' added to the Lists of …
Present the list of new drug submissions (NDSs) that are currently being reviewed.
Understand the decisions to approve or not approve the sale of drugs and medical devices in Canada.
Drug shortages can occur for any number of reasons and can result from problems at any point in the drug …
The Canadian drug supply chain is complex, with distinct roles and responsibilities among many players including manufacturers, wholesalers, hospitals, health …
Briefing binder created for the Minister of National Defence on the occasion of his appearance before the Special Committee on …